Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy

Cancer

Volumn 119, Issue 16, 2013, Pages 3012-3019

  Galsky, Matthew D ^a   Moshier, Erin ^a   Krege, Susan ^b   Lin, Chia Chi ^c   Hahn, Noah ^d   Ecke, Thorsten ^e   Sonpavde, Guru ^f,g   Godbold, James ^a   Oh, William K ^a   Bamias, Aristotle ^h  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Krankenhaus Maria Hilf   (Germany)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d INDIANA UNIVERSITY   (United States)

^e HELIOS Klinikum Bad Saarow   (Germany)

^f US Oncology Research   (United States)

^g TEXAS ONCOLOGY   (United States)

^h UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

bladder cancer; chemotherapy; cisplatin; metastatic; prognosis; urothelial cancer

Indexed keywords

BEVACIZUMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; METHOTREXATE; PACLITAXEL; SORAFENIB; SUNITINIB; VINBLASTINE;

ADULT; AGED; ARTICLE; CALIBRATION; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; FUNCTIONAL STATUS; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; NOMOGRAM; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SURVIVAL TIME; TRANSITIONAL CELL CARCINOMA; VALIDATION PROCESS; VISCERAL METASTASIS;

EID: 84881481853     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28146     Document Type: Article

References (32)

1. Sternberg CN, de Mulder P, Schornagel JH, et al. EORTC Genito-Urinary Cancer Group. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer. 2006; 42: 50-54.
2. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000; 18: 3068-3077.
3. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005; 23: 4602-4608.
4. Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999; 17: 3173-3181.
5. Bellmunt J, Albanell J, Paz-Ares L, et al. Spanish Oncology Genitourinary Group. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer. 2002; 95: 751-757.
6. Roberts JT, von der Maase H, Sengelov L, et al. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer. Ann Oncol. 2006; 17 (suppl 5): v118-v122.
7. Stadler WM, Hayden A, von der Maase H, et al. Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urol Oncol. 2002; 7: 153-157.
8. Iasonos A, Schrag D, Raj GV, Panageas KS,. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008; 26: 1364-1370.
9. Hahn NM, Stadler WM, Zon RT, et al. Hoosier Oncology Group. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol. 2011; 29: 1525-1530.
10. Galsky MD, Hahn NM, Powers T, et al. Gemcitabine, cisplatin, and sunitinib for metastatic urothelial cancer and as preoperative therapy for muscle-invasive bladder cancer. Clin Genitourin Cancer 2013; 11: 175-181.
11. Ecke TH, Bartel P, Koch S, Ruttloff J, Theissig F,. Chemotherapy with gemcitabine, paclitaxel, and cisplatin in the treatment of patients with advanced transitional cell carcinoma of the urothelium. Oncol Rep. 2006; 16: 1381-1388.
12. Krege S, Rexer H, vom Dorp F, et al. Gemcitabine and cisplatin with or without sorafenib in urothelial carcinoma (AUO-AB 31/05) [abstract]. J Clin Oncol. 2010; 28:Pages. Abstract 4574.
13. Lin CC, Hsu CH, Huang CY, et al. Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: an effective regimen with low toxicity. Cancer. 2006; 106: 1269-1275.
14. Lin CC, Hsu CH, Huang CY, Cheng AL, Vogelzang NJ, Pu YS,. Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma. J Urol. 2007; 177: 84-89; discussion 89.
15. Bamias A, Aravantinos G, Deliveliotis C, et al. Hellenic Cooperative Oncology Group. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol. 2004; 22: 220-228.
16. Bamias A, Dafni U, Karadimou A, et al. Prospective open label randomized phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable metastatic or relapsed urothelial cancer: A Hellenic Cooperative Oncology Group study. Ann Oncol. 2013; 24: 1011-1017.
17. Miller AB, Hoogstraten B, Staquet M, Winkler A,. Reporting results of cancer treatment. Cancer. 1981; 47: 207-214.
18. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
19. Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA,. Evaluating the yield of medical tests. JAMA. 1982; 247: 2543-2546.
20. Akdogan B, Dogan HS, Eskicorapci SY, Sahin A, Erkan I, Ozen H,. Prognostic significance of bladder tumor history and tumor location in upper tract transitional cell carcinoma. J Urol. 2006; 176: 48-52.
21. Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/ gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol. 2012; 30: 1107-1113.
22. Catto JW, Azzouzi AR, Amira N, et al. Distinct patterns of microsatellite instability are seen in tumours of the urinary tract. Oncogene. 2003; 22: 8699-8706.
23. Catto JW, Azzouzi AR, Rehman I, et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol. 2005; 23: 2903-2910.
24. Galsky MD, Krege S, Lin CC, et al. Prognostic model for overall survival in patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. J Clin Oncol. (Meeting Abstracts) 2012; 30:Abstract 4524.
25. Granger JM, Kontoyiannis DP,. Etiology and outcome of extreme leukocytosis in 758 nonhematologic cancer patients: a retrospective, single-institution study. Cancer. 2009; 115: 3919-3923.
26. Kasuga I, Makino S, Kiyokawa H, Katoh H, Ebihara Y, Ohyashiki K,. Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma. Cancer. 2001; 92: 2399-2405.
27. Shoenfeld Y, Tal A, Berliner S, Pinkhas J,. Leukocytosis in non hematological malignancies-a possible tumor-associated marker. J Cancer Res Clin Oncol. 1986; 111: 54-58.
28. Goldstein LJ, Gray R, Badve S, et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol. 2008; 26: 4063-4071.
29. Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA,. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst. 2001; 93: 358-366.
30. Sonpavde G, Watson D, Tourtellott M, et al. Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community. Clin Genitourin Cancer. 2012; 10: 1-5.
31. David KA, Milowsky MI, Ritchey J, Carroll PR, Nanus DM,. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol. 2007; 178: 451-454.
32. Galsky MD, Hahn NM, Rosenberg J, et al. Treatment of patients with metastatic urothelial cancer "unfit" for cisplatin-based chemotherapy. J Clin Oncol. 2011; 29: 2432-2438.